182 related articles for article (PubMed ID: 31479408)
1. Treatment Response and Complications after Intradetrusor OnabotulinumtoxinA Injection in Male Patients with Idiopathic Overactive Bladder Syndrome.
Mateu Arrom L; Mayordomo Ferrer O; Sabiote Rubio L; Gutierrez Ruiz C; Martínez Barea V; Palou Redorta J; Errando Smet C
J Urol; 2020 Feb; 203(2):392-397. PubMed ID: 31479408
[TBL] [Abstract][Full Text] [Related]
2. OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial.
Nitti VW; Dmochowski R; Herschorn S; Sand P; Thompson C; Nardo C; Yan X; Haag-Molkenteller C;
J Urol; 2013 Jun; 189(6):2186-93. PubMed ID: 23246476
[TBL] [Abstract][Full Text] [Related]
3. OnabotulinumtoxinA for the Treatment of Patients with Overactive Bladder and Urinary Incontinence: Results of a Phase 3, Randomized, Placebo Controlled Trial.
Nitti VW; Dmochowski R; Herschorn S; Sand P; Thompson C; Nardo C; Yan X; Haag-Molkenteller C;
J Urol; 2017 Feb; 197(2S):S216-S223. PubMed ID: 28012773
[TBL] [Abstract][Full Text] [Related]
4. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.
Chapple C; Sievert KD; MacDiarmid S; Khullar V; Radziszewski P; Nardo C; Thompson C; Zhou J; Haag-Molkenteller C
Eur Urol; 2013 Aug; 64(2):249-56. PubMed ID: 23608668
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of onabotulinumtoxinA injection in patients with refractory overactive bladder: First multicentric study in Turkish population.
Onem K; Bayrak O; Demirtas A; Coskun B; Dincer M; Kocak I; Onur R;
Neurourol Urodyn; 2018 Jan; 37(1):263-268. PubMed ID: 28407394
[TBL] [Abstract][Full Text] [Related]
6. Randomized, double-blind, placebo controlled pilot study of intradetrusor injections of onabotulinumtoxinA for the treatment of refractory overactive bladder persisting following surgical management of benign prostatic hyperplasia.
Chughtai B; Dunphy C; Lee R; Lee D; Sheth S; Marks L; Kaplan SA; Te AE
Can J Urol; 2014 Apr; 21(2):7217-21. PubMed ID: 24775575
[TBL] [Abstract][Full Text] [Related]
7. Safety of Intradetrusor OnabotulinumtoxinA (BTX-A) Injection in the Asymptomatic Patient With a Positive Urine Dip.
Derisavifard S; Giusto LL; Zahner P; Rueb JJ; Goldman HB
Urology; 2020 Jan; 135():38-43. PubMed ID: 31600558
[TBL] [Abstract][Full Text] [Related]
8. The effect of onabotulinumtoxinA according to site of injection in patients with overactive bladder: a systematic review and meta-analysis.
Jo JK; Kim KN; Kim DW; Kim YT; Kim JY; Kim JY
World J Urol; 2018 Feb; 36(2):305-317. PubMed ID: 29124347
[TBL] [Abstract][Full Text] [Related]
9. Bladder instillation of liposome encapsulated onabotulinumtoxina improves overactive bladder symptoms: a prospective, multicenter, double-blind, randomized trial.
Chuang YC; Kaufmann JH; Chancellor DD; Chancellor MB; Kuo HC
J Urol; 2014 Dec; 192(6):1743-9. PubMed ID: 25046622
[TBL] [Abstract][Full Text] [Related]
10. Botulinum toxin (OnabotulinumtoxinA) in the male non-neurogenic overactive bladder: clinical and quality of life outcomes.
Habashy D; Losco G; Tse V; Collins R; Chan L
BJU Int; 2015 Oct; 116 Suppl 3():61-5. PubMed ID: 26176660
[TBL] [Abstract][Full Text] [Related]
11. Oral phenazopyridine vs intravesical lidocaine for bladder onabotulinumtoxinA analgesia: a randomized controlled trial.
Stewart LE; Siddique M; Jacobs KM; Raker CA; Sung VW
Am J Obstet Gynecol; 2022 Aug; 227(2):308.e1-308.e8. PubMed ID: 35580634
[TBL] [Abstract][Full Text] [Related]
12. Durable Efficacy and Safety of Long-Term OnabotulinumtoxinA Treatment in Patients with Overactive Bladder Syndrome: Final Results of a 3.5-Year Study.
Nitti VW; Ginsberg D; Sievert KD; Sussman D; Radomski S; Sand P; De Ridder D; Jenkins B; Magyar A; Chapple C;
J Urol; 2016 Sep; 196(3):791-800. PubMed ID: 27038769
[TBL] [Abstract][Full Text] [Related]
13. Increased risk of large post-void residual urine and decreased long-term success rate after intravesical onabotulinumtoxinA injection for refractory idiopathic detrusor overactivity.
Liao CH; Kuo HC
J Urol; 2013 May; 189(5):1804-10. PubMed ID: 23178902
[TBL] [Abstract][Full Text] [Related]
14. Long-term follow-up of intravesical botulinum toxin-A injections in women with idiopathic overactive bladder symptoms.
Marcelissen TA; Rahnama'i MS; Snijkers A; Schurch B; De Vries P
World J Urol; 2017 Feb; 35(2):307-311. PubMed ID: 27272312
[TBL] [Abstract][Full Text] [Related]
15. Onabotulinumtoxin-A improves health status and urinary symptoms in subjects with refractory overactive bladder: Real-life experience.
Tamburro FR; Castellan P; Neri F; Berardinelli F; Bada M; Sountoulides P; Giuliani N; Finazzi Agrò E; Schips L; Cindolo L
Urologia; 2018 Nov; 85(4):163-168. PubMed ID: 30426883
[TBL] [Abstract][Full Text] [Related]
16. Reduced versus standard intradetrusor OnabotulinumtoxinA injections for treatment of overactive bladder.
DiCarlo-Meacham AM; Dengler KL; Welch EK; Brooks DI; Gruber DD; Osborn DJ; Scarlotta L; Vaccaro CM
Neurourol Urodyn; 2023 Jan; 42(1):366-374. PubMed ID: 36455284
[TBL] [Abstract][Full Text] [Related]
17. Intravesical Injection of OnabotulinumtoxinA (Botulinum Toxin Type A) in Japanese Patients With Refractory Overactive Bladder.
Gotoh D; Torimoto K; Takamatsu N; Onishi K; Morizawa Y; Hori S; Nakai Y; Miyake M; Fujimoto K
In Vivo; 2024; 38(3):1332-1337. PubMed ID: 38688605
[TBL] [Abstract][Full Text] [Related]
18. Urinary retention rates after intravesical onabotulinumtoxinA injection for idiopathic overactive bladder in clinical practice and predictors of this outcome.
Osborn DJ; Kaufman MR; Mock S; Guan MJ; Dmochowski RR; Reynolds WS
Neurourol Urodyn; 2015 Sep; 34(7):675-8. PubMed ID: 24975819
[TBL] [Abstract][Full Text] [Related]
19. Inconsistency in the Definition of Urinary Tract Infection after Intravesical Botulinum Toxin A Injection: A Systematic Review.
Stamm AW; Adelstein SA; Chen A; Lucioni A; Kobashi KC; Lee UJ
J Urol; 2018 Oct; 200(4):809-814. PubMed ID: 29653162
[TBL] [Abstract][Full Text] [Related]
20. Predictive factors of adverse events after intravesical suburothelial onabotulinumtoxina injections for overactive bladder syndrome-A real-life practice of 290 cases in a single center.
Jiang YH; Ong HL; Kuo HC
Neurourol Urodyn; 2017 Jan; 36(1):142-147. PubMed ID: 26417884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
